ONCT - Oncternal Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Oncternal Therapeutics, Inc.

12230 El Camino Real
Suite 300
San Diego, CA 92130
United States

Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. James B. BreitmeyerPres, CEO & DirectorN/AN/A1954
Mr. Richard G. VincentChief Financial OfficerN/AN/A1964
Ms. Lauren G. OtsukiChief Operating OfficerN/AN/AN/A
Dr. Brian Lannutti Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Hazel M. AkerGen. CounselN/AN/A1956
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Oncternal Therapeutics, Inc., a clinical-stage biotechnology company, develops various product candidates for the treatment of cancer. The company's product pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the receptor tyrosine kinase-like orphan receptor 1 (ROR1) that is being evaluated in a Phase I/II clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma; and TK-216, a small-molecule compound that is designed to inhibit E26 transformation-specific oncogene-family oncoproteins, which is being evaluated in a Phase I clinical trial alone and in combination with vincristine to treat Ewing sarcoma, a rare pediatric cancer. It is also developing a chimeric antigen receptor-T product candidate that targets ROR1, which is currently in preclinical development for treating hematologic cancers and solid tumors. The company is headquartered in San Diego, California.

Corporate Governance

Oncternal Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.